Multiple Myeloma Clinical Trial
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Summary
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18
Confirmed diagnosis of multiple myeloma
Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy
Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial
Exclusion Criteria:
Previous receipt of anthracycline chemotherapy
Previous receipt of carfilzomib
Four or more previous lines of therapy
Active pregnancy at the time of enrollment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Chicago Illinois, 60637, United States
How clear is this clinincal trial information?
